Hepatitis Medications

Hepatitis A and E: prevention over treatment

Hepatitis A and E cause acute, self-limited liver inflammation that resolves on its own in an immunocompetent host. No specific antiviral targets these viruses in routine practice. The focus is prevention: hepatitis A vaccination for at-risk individuals and travelers, plus hygiene measures (safe water, handwashing, sanitation) limiting fecal-oral spread. Acute care is supportive — rest, hydration, avoiding hepatotoxic substances — while the liver clears itself.

Hepatitis B: chronic suppression, not cure

Hepatitis B often becomes chronic, especially when acquired early in life. The mainstay of management is oral nucleoside/nucleotide analogues such as tenofovir and entecavir, which inhibit viral reverse transcriptase and suppress replication long-term. These agents rarely eradicate the virus, which persists inside liver cell nuclei, so therapy is usually indefinite and stopping it can allow rebound. A finite-duration alternative is peginterferon, an immune-modulating injectable that can produce durable control in some patients but carries substantial adverse effects — flu-like symptoms, cytopenias, mood disturbances — limiting its use versus the better-tolerated oral analogues.

The single most important safety concept is reactivation risk. A patient with current or prior hepatitis B who receives immunosuppressive therapy — chemotherapy, corticosteroids, or B-cell-depleting agents such as rituximab — can experience a sudden resurgence of viral replication causing severe, sometimes fatal, liver injury. Screening for hepatitis B markers is required before starting such therapy, and patients who test positive may need prophylactic antiviral therapy before and during that course.

Hepatitis C: the direct-acting antiviral era

Older interferon-based regimens have largely been replaced by oral direct-acting antivirals targeting specific viral proteins: sofosbuvir (a polymerase inhibitor), ledipasvir and velpatasvir (NS5A inhibitors), and combinations such as glecaprevir-pibrentasvir (protease inhibitor plus NS5A inhibitor). These are given as a short, defined course achieving very high sustained clearance with minimal toxicity. Remaining issues are practical: drug interactions (amiodarone with certain regimens has been linked to serious slow heart rhythms; acid-suppressants can impair absorption; statin levels can rise; enzyme-inducing drugs can push antiviral levels below effective concentrations), strict adherence to complete the short course, and access and cost that can limit timely treatment.

Autoimmune hepatitis and general principles

Autoimmune hepatitis is not viral — it results from immune-mediated attack on liver tissue — and is managed with corticosteroids to induce remission, often paired with azathioprine as a steroid-sparing agent. Across all liver disease, hepatoprotective principles apply: avoiding alcohol, vaccinating against hepatitis A and B, and avoiding unnecessary hepatotoxic exposures. Key nursing point: liver disease broadly alters drug metabolism, so many medications require dose reduction, closer monitoring, or avoidance in significant hepatic impairment, regardless of the drug's target.